Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

NVDAMillionaire Jul. 29 at 5:18 PM

$GUTS Excellent article that nails exactly where GUTS stands right now. So if you want to update your GUTS knowledge or get acquainted with GUTS, this is a must read. https://beyondspx.com/article/fractyl-health-targeting-metabolic-disease-root-causes-beyond-chronic-glp-1s-nasdaq-guts

1 · Reply

BioRich Jul. 29 at 5:02 PM

$GUTS Not gonna lie, I like that we're sitting at $1.85, and down almost 7%. Much better feeling than down 7% and being sub-1. This is a $4 stock on a sneeze so buckle up folks. Big things ahead and this management team is poised to get us there. For those new, welcome. I believe you've made a great decision. Patience will prevail. For those long, congrats riding the wave. We're onto something big and I believe our patience will be rewarded handsomely. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI

1 · Reply

nickexus Jul. 25 at 11:56 AM

$GUTS getting ready after the breakout

0 · Reply

Clubowner Jul. 23 at 1:48 AM

$GUTS partnership is the end game. at this price the odds are in favor to own.

0 · Reply

BioHuntingTwits Jul. 18 at 11:08 PM

$GUTS Looking at REVITA and previous data - I believe that the treatment the company is developing could be a breakthrough for patients with diabetes and obesity. There is a good chance that the expected results this year and later in 2026 will be positive. It looks like a promising treatment and novel approach. But there is still a risk of public offering bcz money is running out into 2026. If partnership occurs, dilution might not be necessary.

2 · Reply

Codaman80 Jul. 18 at 4:41 PM

$GUTS What do you guys think? Is a $6.00 target price too bullish by Halloween?

1 · Reply

LarryFeelTheHeaton Jul. 18 at 7:10 AM

$GUTS

0 · Reply

jmmoore4 Jul. 17 at 7:40 PM

$GUTS ⬆️😎

0 · Reply

BioRich Jul. 17 at 6:04 PM

$GUTS Just a friendly reminder that this is what I signaled a few days ago. We're about to go on a heater. Buckle up folks. Always a partnership/BO target, on top of excellent organic growth so make sure to keep this on your radar and add as you see fit. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $PFE $LLY $NVO

0 · Reply

CarolinesGrippy Jul. 17 at 3:39 PM

$GUTS here’s the bull thesis and all you need to know for the longterm: Thiel is backing this hugely. Thiel doesn’t lose.

3 · Reply

Fractyl Health: Speculative Buy With Binary Risk

Jun 23, 2025, 7:40 AM EDT - 5 weeks ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 5 weeks ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 6 weeks ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 7 weeks ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 2 months ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 2 months ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 2 months ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 2 months ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 3 months ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 3 months ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 4 months ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 5 months ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 5 months ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 5 months ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 6 months ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 8 months ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 8 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 8 months ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 9 months ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 9 months ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 9 months ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 9 months ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 9 months ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Sep 24, 2024, 7:00 AM EDT - 11 months ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 3, 2024, 7:00 AM EDT - 11 months ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Aug 14, 2024, 9:27 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

Jun 23, 2024, 1:30 PM EDT - 1 year ago

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's

May 20, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

May 13, 2024, 10:37 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:00 PM EDT - 1 year ago

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

May 13, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

May 8, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

May 7, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

Apr 30, 2024, 8:38 AM EDT - 1 year ago

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 1, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Mar 19, 2024, 8:08 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

IVP OM PACB

Mar 12, 2024, 2:06 PM EDT - 1 year ago

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Mar 12, 2024, 8:38 AM EDT - 1 year ago

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Feb 20, 2024, 8:38 AM EST - 1 year ago

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

Feb 4, 2024, 6:16 AM EST - 1 year ago

U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings

AS AHR AMDI ANRO FBLG FLUT KYTX

NVDAMillionaire Jul. 29 at 5:18 PM

1 · Reply

BioRich Jul. 29 at 5:02 PM

1 · Reply

nickexus Jul. 25 at 11:56 AM

$GUTS getting ready after the breakout

0 · Reply

Clubowner Jul. 23 at 1:48 AM

$GUTS partnership is the end game. at this price the odds are in favor to own.

0 · Reply

BioHuntingTwits Jul. 18 at 11:08 PM

2 · Reply

Codaman80 Jul. 18 at 4:41 PM

$GUTS What do you guys think? Is a $6.00 target price too bullish by Halloween?

1 · Reply

LarryFeelTheHeaton Jul. 18 at 7:10 AM

$GUTS

0 · Reply

jmmoore4 Jul. 17 at 7:40 PM

$GUTS ⬆️😎

0 · Reply

BioRich Jul. 17 at 6:04 PM

0 · Reply

CarolinesGrippy Jul. 17 at 3:39 PM

$GUTS here’s the bull thesis and all you need to know for the longterm: Thiel is backing this hugely. Thiel doesn’t lose.

3 · Reply

BioRich Jul. 16 at 4:11 PM

$JMIA Bought more on this hidden gem. Still new to the ticker. Absolutely new to the sector. Excited about what I've read so far. I see strong organic growth and the ever-present BO opportunity is always enticing. For those looking at Bios (my wheelhouse), take a look at $CAPR, $GUTS, $VNDA and $MIST. Each is a homerun in my opinion. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers!

5 · Reply

SoldierOfFortune1985 Jul. 15 at 3:19 PM

$GUTS

1 · Reply

jmmoore4 Jul. 15 at 12:17 AM

$GUTS Bullish Sentiment?! It’s about time!!!! ✅

0 · Reply

Itinerant Jul. 14 at 6:44 PM

$GUTS This is interesting but it has a rather high valuation given the early stage and the high burn rate. Any comments in response?

1 · Reply

SoldierOfFortune1985 Jul. 14 at 6:17 PM

$GUTS

2 · Reply

GreenEnergy2022 Jul. 14 at 5:32 PM

$GUTS Dont trust BioRich, look up his earlier post here: He says GUTS have several years of cash runway, but company Q10 says only until Q4 2025 ... Look it up yourself if you dont believe.

3 · Reply

jmmoore4 Jul. 14 at 5:14 PM

$GUTS @BioRich, wouldn’t it be crazy if this shot up higher than $ALT?! 😅

1 · Reply

BioRich Jul. 14 at 4:27 PM

$GUTS HUGE reversal coming on the charts. This is about to explode. Great stock, even better product. Truly unique in the competitive Obesity sector with their weight loss retention procedure. This is the TRUE next generation in Obesity/Weight Loss. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $IBB $PFE $LLY

3 · Reply

BioRich Jul. 13 at 9:34 PM

$GUTS Looks like Fractyl's Founder and President is presenting at the Obesity and Weight Loss Drug Development Summit in Boston tomorrow. 11am's presentation is: "Why Physiologically-Regulated GLP-1 May Improve Efficacy and Tolerability & Manage Side Effects". This impressive presentation looks to highlight the importance and differentiation of Fractyl's approach to successful weight loss and weight loss retention, the latter of which will benefit $NVO and $LLY users. Below is more detail regarding the presentation. The GUTS train keeps chugging along! Cheers! https://web.hansonwadegroup.com/rs/355-DOS-429/images/3rd-Obesity-%26-Weight-Loss-Drug-Development-Summit-Full-Event-Guide.pdf $XBI $ALT

5 · Reply

Gaelic73 Jul. 8 at 5:36 PM

$GUTS What causes the drop from $2.88 in early June?

1 · Reply

jmmoore4 Jul. 5 at 9:30 PM

$GUTS Bullish Hammer followed by a Bullish Doji = 😉

0 · Reply

jmmoore4 Jul. 2 at 3:46 PM

$GUTS ⬆️⬆️⬆️⬆️🔜

0 · Reply

Market Cap	88.65M
Revenue (ttm)	90,000.00
Net Income (ttm)	-68.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-76,322.22%
Debt to Equity Ratio	1.06

Volume	113,800
Avg Vol	506,732
Day's Range	N/A - N/A
Shares Out	48.98M
Stochastic %K	24%
Beta	1.66
Analysts	Strong Sell
Price Target	$9.33